Filgrastim Biosimilars Global Market Report 2022 – By Application (Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Type Of Manufacturing (In-House Manufacturing, Contract Manufacturing Oraganization) – Market Size, Trends, And Global Forecast 2022-2026

Starting Price : $5000.00 | Pages : 150 | Published : February 2022 | SKU CODE : | Delivery Time: 2-3 business days | Format :


The filgrastim biosimilars market consists of sales of filgrastim biosimilars and related services by entities (organizations, sole traders and partnerships) that manufacture filgrastim biosimilars. Filgrastim biosimilar treatment is used to stimulate the bone marrow to produce more neutrophils (white blood cells) to fight infection in patients undergoing chemotherapy for cancer treatment. Only goods and services traded between entities or sold to end consumers are included.

The main types of manufacturing in filgrastim biosimilar are in-house manufacturing and contract manufacturing organization. A contract manufacturing organisation, also known as a contract development and manufacturing organisation, is a corporation which provides entire services to other pharma firms on a contractual basis, from drug discovery to drug production. The different applications include oncology, chronic and autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases, others and is distributed through various channels such as hospital pharmacy, retail pharmacy, online pharmacy.

The global filgrastim biosimilars market size is expected to grow from $0.75 billion in 2021 to $0.88 billion in 2022 at a compound annual growth rate (CAGR) of 17.2%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The filgrastim biosimilars market is expected to reach $1.19 billion in 2026 at a CAGR of 8.0%.

Government initiatives for the development of biosimilars are expected to drive the filgrastim biosimilars market over coming years. Governments worldwide are focusing on the development of biosimilars attributing to their cost-effective nature. The US Food and Drug Administration (FDA) launched a Biosimilar Action Plan, to increase treatment options. The Australian government is committed to the Biosimilar Awareness Initiative and they improved their commitment by supporting the Generic and Biosimilar Medicines Association through a grant of $5 million to accept increased general biosimilar education and activities that promote the suitable dispensing, prescription and use of biosimilar medicines. Hence, the government initiatives for the development of biosimilars aids in the increased production and awareness which in turn supported the growth of the filgrastim biosimilars market.

Stringent regulations imposed on approvals of biosimilars is anticipated to hinder the growth of the filgrastim biosimilar market in the forecast period. The governments of different regions impose different rules regarding the production and use of biologics and biosimilars. Further, issues such as patent infringement or agreement issues restrict the manufacturers of biosimilars from commercializing the government-approved biosimilars. The US Food and Drug Administration requires a double regulatory approval for biosimilars, restricting the use of biosimilars as an interchangeable drug to biologics, whereas, in Europe, the European Medicines Agency (EMA) approves biosimilars as interchangeable products for biologics. For instance, Sandoz got an USFDA approval for its 1st biosimilar ZarxioTM (filgrastim-sndz) of original biologic Neupogen. The consent depended on a comprehensive package of analytical, nonclinical, and clinical information, which verified that Zarxio is highly similar to the US-licensed reference product. To get this approval Sandoz even had to fight a legal battle with Amgen who claims that Sandoz has infringed its manufacturing process. These kinds of hurdles can restrict the growth of the filgrastim biosimilar market.

Companies in the pegfilgrastim biosimilar market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as academic and research institutions in this market by way of partnerships, in or out licensing deals, this trend has been increasing over the recent years. For instance, in April 2020, Biocon, an India based biopharmaceutical company partnered with Mylan, a US based generic and specialty pharmaceuticals company to introduce Fulphila, biosimilar pegfilgrastim in Australia. Fulphila has been licenced by the Therapeutic Goods Administration for the therapy of oncology patients who have had chemotherapy in order to shorten the length of acute neutropenia and hence the risk of infection, as evidenced by febrile neutropenia.

In January 2019, Kashiv Pharma, US-based biopharmaceuticals Research Company, acquired Adello biologics for an undisclosed amount. The new company will be known as Kashiv Biosciences. The deal will help Kashiv BioSciences in expanding its business offering in including drug delivery platforms consolidating delayed-release technology and gastric retention systems that improve the efficacy and safety of known drugs, the pipeline of seven development products targeting unmet clinical needs. Adello Biologics was founded in 2012 and is a biotechnology company that works on developing biosimilars including filgrastims. The company is headquartered in Piscataway, New Jersey.

Major players in the filgrastim biosimilars market are Cadila Pharmaceuticals, Dr. Reddy's Laboratories, Intas Biopharmaceuticals, Sandoz, Amgen Inc., Dr. Reddy's Laboratories Ltd, Intas Pharmaceuticals, Emcure Pharmaceuticals Ltd., Biocon and Aryogen Biopharma.

North America was the largest region in the filgrastim biosimilars market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the filgrastim biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The global filgrastim biosimilars market is segmented -

1) By Application: Oncology, Chronic and Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, Others

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By Type of Manufacturing: In-House Manufacturing, Contract Manufacturing Oraganization

    Table Of Contents

    1. Executive Summary

    2. Filgrastim Biosimilars Market Characteristics

    3. Filgrastim Biosimilars Market Trends And Strategies

    4. Impact Of COVID-19 On Filgrastim Biosimilars

    5. Filgrastim Biosimilars Market Size And Growth

    5.1. Global Filgrastim Biosimilars Historic Market, 2016-2021, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Filgrastim Biosimilars Forecast Market, 2021-2026F, 2031F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Filgrastim Biosimilars Market Segmentation

    6.1. Global Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Oncology

    Chronic and Autoimmune Diseases

    Blood Disorders

    Growth Hormone Deficiency

    Infectious Diseases

    Others

    6.2. Global Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Hospital Pharmacy

    Retail Pharmacy

    Online Pharmacy

    6.3. Global Filgrastim Biosimilars Market, Segmentation By Type of Manufacturing, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    In-House Manufacturing

    Contract Manufacturing Oraganization

    7. Filgrastim Biosimilars Market Regional And Country Analysis

    7.1. Global Filgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    7.2. Global Filgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8. Asia-Pacific Filgrastim Biosimilars Market

    8.1. Asia-Pacific Filgrastim Biosimilars Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8.3. Asia-Pacific Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    9. China Filgrastim Biosimilars Market

    9.1. China Filgrastim Biosimilars Market Overview

    9.2. China Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    9.3. China Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    10. India Filgrastim Biosimilars Market

    10.1. India Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    10.2. India Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11. Japan Filgrastim Biosimilars Market

    11.1. Japan Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11.2. Japan Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12. Australia Filgrastim Biosimilars Market

    12.1. Australia Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12.2. Australia Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13. Indonesia Filgrastim Biosimilars Market

    13.1. Indonesia Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13.2. Indonesia Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14. South Korea Filgrastim Biosimilars Market

    14.1. South Korea Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14.2. South Korea Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15. Western Europe Filgrastim Biosimilars Market

    15.1. Western Europe Filgrastim Biosimilars Market Overview

    15.2. Western Europe Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15.3. Western Europe Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16. UK Filgrastim Biosimilars Market

    16.1. UK Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16.2. UK Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17. Germany Filgrastim Biosimilars Market

    17.1. Germany Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17.2. Germany Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18. France Filgrastim Biosimilars Market

    18.4. France Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18.5. France Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19. Eastern Europe Filgrastim Biosimilars Market

    19.1. Eastern Europe Filgrastim Biosimilars Market Overview

    19.2. Eastern Europe Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19.3. Eastern Europe Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20. Russia Filgrastim Biosimilars Market

    20.1. Russia Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20.2. Russia Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21. North America Filgrastim Biosimilars Market

    21.1. North America Filgrastim Biosimilars Market Overview

    21.2. North America Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21.3. North America Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22. USA Filgrastim Biosimilars Market

    22.1. USA Filgrastim Biosimilars Market Overview

    22.2. USA Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22.3. USA Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23. South America Filgrastim Biosimilars Market

    23.1. South America Filgrastim Biosimilars Market Overview

    23.2. South America Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23.3. South America Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24. Brazil Filgrastim Biosimilars Market

    24.1. Brazil Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24.2. Brazil Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25. Middle East Filgrastim Biosimilars Market

    25.1. Middle East Filgrastim Biosimilars Market Overview

    25.2. Middle East Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25.3. Middle East Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26. Africa Filgrastim Biosimilars Market

    26.1. Africa Filgrastim Biosimilars Market Overview

    26.2. Africa Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26.3. Africa Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    27. Filgrastim Biosimilars Market Competitive Landscape And Company Profiles

    27.1. Filgrastim Biosimilars Market Competitive Landscape

    27.2. Filgrastim Biosimilars Market Company Profiles

    27.2.1. Cadila Pharmaceuticals

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Dr. Reddy's Laboratories

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Intas Biopharmaceuticals

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Sandoz

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Amgen Inc.

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Filgrastim Biosimilars Pipeline Analysis

    29. Key Mergers And Acquisitions In The Filgrastim Biosimilars Market

    30. Filgrastim Biosimilars Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Research Inquiries

    31.4. The Business Research Company

    31.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2016-2021, $ Billion
  • Table 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Table 3: Global Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 4: Global Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 5: Global Filgrastim Biosimilars Market, Segmentation By Type of Manufacturing, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 6: Global Filgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 7: Global Filgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 8: Asia-Pacific, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 9: Asia-Pacific, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 10: China, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 11: China, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 12: India, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 13: India, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 14: Japan, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 15: Japan, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 16: Australia, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 17: Australia, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 18: Indonesia, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 19: Indonesia, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 20: South Korea, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 21: South Korea, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 22: Western Europe, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 23: Western Europe, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 24: UK, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 25: UK, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 26: Germany, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 27: Germany, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 28: France, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 29: France, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 30: Eastern Europe, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 31: Eastern Europe, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 32: Russia, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 33: Russia, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 34: North America, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 35: North America, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 36: USA, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 37: USA, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 38: South America, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 39: South America, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 40: Brazil, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 41: Brazil, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 42: Middle East, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 43: Middle East, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 44: Africa, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 45: Africa, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 46: Cadila Pharmaceuticals Financial Performance
  • Table 47: Dr. Reddy's Laboratories Financial Performance
  • Table 48: Intas Biopharmaceuticals Financial Performance
  • Table 49: Sandoz Financial Performance
  • Table 50: Amgen Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2016-2021, $ Billion
  • Figure 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Figure 3: Global Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 4: Global Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 5: Global Filgrastim Biosimilars Market, Segmentation By Type of Manufacturing, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 6: Global Filgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 7: Global Filgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 8: Asia-Pacific, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 9: Asia-Pacific, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 10: China, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 11: China, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 12: India, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 13: India, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 14: Japan, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 15: Japan, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 16: Australia, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 17: Australia, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 18: Indonesia, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 19: Indonesia, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 20: South Korea, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 21: South Korea, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 22: Western Europe, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 23: Western Europe, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 24: UK, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 25: UK, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 26: Germany, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 27: Germany, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 28: France, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 29: France, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 30: Eastern Europe, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 31: Eastern Europe, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 32: Russia, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 33: Russia, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 34: North America, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 35: North America, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 36: USA, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 37: USA, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 38: South America, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 39: South America, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 40: Brazil, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 41: Brazil, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 42: Middle East, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 43: Middle East, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 44: Africa, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 45: Africa, Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 46: Cadila Pharmaceuticals Financial Performance
  • Figure 47: Dr. Reddy's Laboratories Financial Performance
  • Figure 48: Intas Biopharmaceuticals Financial Performance
  • Figure 49: Sandoz Financial Performance
  • Figure 50: Amgen Inc. Financial Performance
Global Anti-Infective Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Cell and Gene Therapy Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Pharmaceutical Drugs And Biologics Logistics Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Pharmaceutical Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Microbiome Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Therapeutic Proteins Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Pegfilgrastim Biosimilars Market 2022 - By Application (Chemotherapy Induced Neutropenia, Transplantation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies), And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Biosimilars Global Market Report 2022 – By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Types (Human Growth Hormone, Erythropoietin, Monoclonal antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor), By Application (Oncology, Chronic and Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2022 – By Product (Adalimumab Biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, Others), Infliximab Biosimilars (Inflectra, Renflexis, Ixifi, Avsola), Cipleumab (Erelzi, Eticovo)), By Application (Crohn’S Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Biosimilar Hormones Global Market Report 2022 – By Type (Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars), By Application (Research & Biotechnology, Diagnostics, Biocatalysts, Therapeutics), By Distribution Channel (Hospital And Retail Pharmacy, Online Pharmacy/epharmacy, Speciality Clinics) – Market Size, Trends, And Global Forecast 2022-2026
View Report
G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2022 – By Type (Lenograstim (Granocyte), Filgrastim (Neupogen, Zarzio, Nivestim, Accofil), Long Acting (Pegylated) Filgrastim (Pegfilgrastim, Neulasta, Pelmeg, Ziextenco), Lipegfilgrastim (Lonquex)), By Application (Oncological Diseases, Blood Disorders, Growth Hormone Deficiencies, Chronic And Autoimmune Disorders, Others), By Product: Tablet, Capsule, Others) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Neutropenia Biologic Drug Treatment Global Market Report 2022 – By Drug Type (Filgrastim, Pegfilgrastim, Lenograstim, Lipegfilgrastim, Sargramostim), By Treatment Type (Antibiotic Drugs, Granulocyte-Colony-Stimulating Factor (G-CSF), Antifungal Drugs), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Oncology Biosimilars Global Market Report 2022 – By Drug Type (Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)), By Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer), By Distribution Type (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Oral Biologics & Biosimilars Market Global Report 2020 - By Therapy (Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors), By Disease (Asthma, Crohn`S Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis)
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)